<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet href="/rss.css" type="text/css"?>
<rdf:RDF xmlns="http://purl.org/rss/1.0/"
    xmlns:cc="http://web.resource.org/cc/"
    xmlns:dc="http://purl.org/dc/elements/1.1/"
    xmlns:extra="http://www.w3.org/1999/xhtml"
    xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/"
    xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#">
    <channel rdf:about="http://www.molecularautism.com/feeds/mostaccessed/journal?quantity=&amp;format=rss&amp;version=">
        <title>Molecular Autism - Most accessed articles</title>
        <link>http://www.molecularautism.com</link>
        <description>The most accessed research articles published by Molecular Autism</description>
        <dc:date>2012-04-02T00:00:00Z</dc:date>
        <items>
            <rdf:Seq>
                                <rdf:li rdf:resource="http://www.molecularautism.com/content/3/1/2" />
                                <rdf:li rdf:resource="http://www.molecularautism.com/content/2/1/15" />
                                <rdf:li rdf:resource="http://www.molecularautism.com/content/2/1/1" />
                                <rdf:li rdf:resource="http://www.molecularautism.com/content/2/1/7" />
                                <rdf:li rdf:resource="http://www.molecularautism.com/content/2/1/18" />
                                <rdf:li rdf:resource="http://www.molecularautism.com/content/1/1/12" />
                                <rdf:li rdf:resource="http://www.molecularautism.com/content/3/1/1" />
                                <rdf:li rdf:resource="http://www.molecularautism.com/content/1/1/13" />
                                <rdf:li rdf:resource="http://www.molecularautism.com/content/1/1/15" />
                                <rdf:li rdf:resource="http://www.molecularautism.com/content/2/1/4" />
                            </rdf:Seq>
        </items>
                 <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </channel>
        <item rdf:about="http://www.molecularautism.com/content/3/1/2">
        <title>Evidence of novel fine-scale structural variation at autism spectrum disorder candidate loci</title>
        <description>Background:
Autism spectrum disorders (ASD) represent a group of neurodevelopmental disorders characterized by a core set of social-communicative and behavioral impairments. Gamma-aminobutyric acid (GABA) is the major inhibitory neurotransmitter in the brain, acting primarily via the GABA receptors (GABR). Multiple lines of evidence, including altered GABA and GABA receptor expression in autistic patients, indicate that the GABAergic system may be involved in the etiology of autism.
Methods:
As copy number variations (CNVs), particularly rare and de novo CNVs, have now been implicated in ASD risk, we examined the GABA receptors and genes in related pathways for structural variation that may be associated with autism. We further extended our candidate gene set to include 19 genes and regions that had either been directly implicated in the autism literature or were directly related (via function or ancestry) to these primary candidates. For the high resolution CNV screen we employed custom-designed 244 k comparative genomic hybridization (CGH) arrays. Collectively, our probes spanned a total of 11 Mb of GABA-related and additional candidate regions with a density of approximately one probe every 200 nucleotides, allowing a theoretical resolution for detection of CNVs of approximately 1 kb or greater on average. One hundred and sixty-eight autism cases and 149 control individuals were screened for structural variants. Prioritized CNV events were confirmed using quantitative PCR, and confirmed loci were evaluated on an additional set of 170 cases and 170 control individuals that were not included in the original discovery set. Loci that remained interesting were subsequently screened via quantitative PCR on an additional set of 755 cases and 1,809 unaffected family members.
Results:
Results include rare deletions in autistic individuals at JAKMIP1, NRXN1, Neuroligin4Y, OXTR, and ABAT. Common insertion/deletion polymorphisms were detected at several loci, including GABBR2 and NRXN3. Overall, statistically significant enrichment in affected vs. unaffected individuals was observed for NRXN1 deletions.
Conclusions:
These results provide additional support for the role of rare structural variation in ASD.</description>
        <link>http://www.molecularautism.com/content/3/1/2</link>
                <dc:creator>Dale Hedges</dc:creator>
                <dc:creator>Kara Hamilton-Nelson</dc:creator>
                <dc:creator>Stephanie Sacharow</dc:creator>
                <dc:creator>Laura Nations</dc:creator>
                <dc:creator>Gary Beecham</dc:creator>
                <dc:creator>Zhanna Kozhekbaeva</dc:creator>
                <dc:creator>Brittany Butler</dc:creator>
                <dc:creator>Holly Cukier</dc:creator>
                <dc:creator>Patrice Whitehead</dc:creator>
                <dc:creator>Deqiong Ma</dc:creator>
                <dc:creator>James Jaworski</dc:creator>
                <dc:creator>Lubov Nathanson</dc:creator>
                <dc:creator>Joycelyn Lee</dc:creator>
                <dc:creator>Stephen Hauser</dc:creator>
                <dc:creator>Jorge Oksenberg</dc:creator>
                <dc:creator>Michael Cuccaro</dc:creator>
                <dc:creator>Jonathan Haines</dc:creator>
                <dc:creator>John Gilbert</dc:creator>
                <dc:creator>Margaret Pericak-Vance</dc:creator>
                <dc:source>Molecular Autism 2012, null:2</dc:source>
        <dc:date>2012-04-02T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/2040-2392-3-2</dc:identifier>
                            <dc:title>Novel structural variation in autism candidate genes</dc:title>
                            <dc:description>Support for the role of rare structural variants at multiple genomic loci in autism spectrum disorders, and in particular the significant enrichment of rare exonic deletions in NRXN1 in autistic vs. non-autistic individuals.</dc:description>
                <prism:require>/content/figures/2040-2392-3-2-toc.gif</prism:require>
                <prism:publicationName>Molecular Autism</prism:publicationName>
        <prism:issn>2040-2392</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>2</prism:startingPage>
        <prism:publicationDate>2012-04-02T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.molecularautism.com/content/2/1/15">
        <title>Facial phenotypes in subgroups of pre-pubertal boys with autism spectrum disorders are correlated with clinical phenotypes</title>
        <description>Background:
The brain develops in concert and in coordination with the developing facial tissues, with each influencing the development of the other and sharing genetic signaling pathways. Autism spectrum disorders (ASDs) result from alterations in the embryological brain, suggesting that the development of the faces of children with ASD may result in subtle facial differences compared to typically developing children. In this study, we tested two hypotheses. First, we asked whether children with ASD display a subtle but distinct facial phenotype compared to typically developing children. Second, we sought to determine whether there are subgroups of facial phenotypes within the population of children with ASD that denote biologically discrete subgroups.
Methods:
The 3dMD cranial System was used to acquire three-dimensional stereophotogrammetric images for our study sample of 8- to 12-year-old boys diagnosed with essential ASD (n = 65) and typically developing boys (n = 41) following approved Institutional Review Board protocols. Three-dimensional coordinates were recorded for 17 facial anthropometric landmarks using the 3dMD Patient software. Statistical comparisons of facial phenotypes were completed using Euclidean Distance Matrix Analysis and Principal Coordinates Analysis. Data representing clinical and behavioral traits were statistically compared among groups by using &#967;2 tests, Fisher&apos;s exact tests, Kolmogorov-Smirnov tests and Student&apos;s t-tests where appropriate.
Results:
First, we found that there are significant differences in facial morphology in boys with ASD compared to typically developing boys. Second, we also found two subgroups of boys with ASD with facial morphology that differed from the majority of the boys with ASD and the typically developing boys. Furthermore, membership in each of these distinct subgroups was correlated with particular clinical and behavioral traits.
Conclusions:
Boys with ASD display a facial phenotype distinct from that of typically developing boys, which may reflect alterations in the prenatal development of the brain. Subgroups of boys with ASD defined by distinct facial morphologies correlated with clinical and behavioral traits, suggesting potentially different etiologies and genetic differences compared to the larger group of boys with ASD. Further investigations into genes involved in neurodevelopment and craniofacial development of these subgroups will help to elucidate the causes and significance of these subtle facial differences.</description>
        <link>http://www.molecularautism.com/content/2/1/15</link>
                <dc:creator>Kristina Aldridge</dc:creator>
                <dc:creator>Ian George</dc:creator>
                <dc:creator>Kimberly Cole</dc:creator>
                <dc:creator>Jordan Austin</dc:creator>
                <dc:creator>T Nicole Takahashi</dc:creator>
                <dc:creator>Ye Duan</dc:creator>
                <dc:creator>Judith Miles</dc:creator>
                <dc:source>Molecular Autism 2011, null:15</dc:source>
        <dc:date>2011-10-14T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/2040-2392-2-15</dc:identifier>
                            <dc:title>The face of autism</dc:title>
                            <dc:description>A distinctive facial phenotype in boys with autism, which differs from that of typically developing boys, may reflect alterations in embryologic brain development in children with autism spectrum disorders.</dc:description>
                <prism:require>/content/figures/2040-2392-2-15-toc.gif</prism:require>
                <prism:publicationName>Molecular Autism</prism:publicationName>
        <prism:issn>2040-2392</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>15</prism:startingPage>
        <prism:publicationDate>2011-10-14T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.molecularautism.com/content/2/1/1">
        <title>A noise-reduction GWAS analysis implicates altered regulation of neurite outgrowth and guidance in autism</title>
        <description>Background:
Genome-wide Association Studies (GWAS) have proved invaluable for the identification of disease susceptibility genes. However, the prioritization of candidate genes and regions for follow-up studies often proves difficult due to false-positive associations caused by statistical noise and multiple-testing. In order to address this issue, we propose the novel GWAS noise reduction (GWAS-NR) method as a way to increase the power to detect true associations in GWAS, particularly in complex diseases such as autism.
Methods:
GWAS-NR utilizes a linear filter to identify genomic regions demonstrating correlation among association signals in multiple datasets. We used computer simulations to assess the ability of GWAS-NR to detect association against the commonly used joint analysis and Fisher&apos;s methods. Furthermore, we applied GWAS-NR to a family-based autism GWAS of 597 families and a second existing autism GWAS of 696 families from the Autism Genetic Resource Exchange (AGRE) to arrive at a compendium of autism candidate genes. These genes were manually annotated and classified by a literature review and functional grouping in order to reveal biological pathways which might contribute to autism aetiology.
Results:
Computer simulations indicate that GWAS-NR achieves a significantly higher classification rate for true positive association signals than either the joint analysis or Fisher&apos;s methods and that it can also achieve this when there is imperfect marker overlap across datasets or when the closest disease-related polymorphism is not directly typed. In two autism datasets, GWAS-NR analysis resulted in 1535 significant linkage disequilibrium (LD) blocks overlapping 431 unique reference sequencing (RefSeq) genes. Moreover, we identified the nearest RefSeq gene to the non-gene overlapping LD blocks, producing a final candidate set of 860 genes. Functional categorization of these implicated genes indicates that a significant proportion of them cooperate in a coherent pathway that regulates the directional protrusion of axons and dendrites to their appropriate synaptic targets.
Conclusions:
As statistical noise is likely to particularly affect studies of complex disorders, where genetic heterogeneity or interaction between genes may confound the ability to detect association, GWAS-NR offers a powerful method for prioritizing regions for follow-up studies. Applying this method to autism datasets, GWAS-NR analysis indicates that a large subset of genes involved in the outgrowth and guidance of axons and dendrites is implicated in the aetiology of autism.</description>
        <link>http://www.molecularautism.com/content/2/1/1</link>
                <dc:creator>John Hussman</dc:creator>
                <dc:creator>Ren-Hua Chung</dc:creator>
                <dc:creator>Anthony Griswold</dc:creator>
                <dc:creator>James Jaworkski</dc:creator>
                <dc:creator>Daria Salyakina</dc:creator>
                <dc:creator>Deqiong Ma</dc:creator>
                <dc:creator>Ioanna Konidari</dc:creator>
                <dc:creator>Patrice Whitehead</dc:creator>
                <dc:creator>Jeffery Vance</dc:creator>
                <dc:creator>Eden Martin</dc:creator>
                <dc:creator>Michael Cuccaro</dc:creator>
                <dc:creator>John Gilbert</dc:creator>
                <dc:creator>Jonathan Haines</dc:creator>
                <dc:creator>Margaret Pericak-Vance</dc:creator>
                <dc:source>Molecular Autism 2011, null:1</dc:source>
        <dc:date>2011-01-19T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/2040-2392-2-1</dc:identifier>
                                <prism:require>/content/figures/2040-2392-2-1-toc.gif</prism:require>
                <prism:publicationName>Molecular Autism</prism:publicationName>
        <prism:issn>2040-2392</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>1</prism:startingPage>
        <prism:publicationDate>2011-01-19T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.molecularautism.com/content/2/1/7">
        <title>Histopathologic characterization of the BTBR mouse model of autistic-like behavior reveals selective changes in neurodevelopmental proteins and adult hippocampal neurogenesis</title>
        <description>Background:
The inbred mouse strain BTBR T+ tf/J (BTBR) exhibits behavioral deficits that mimic the core deficits of autism. Neuroanatomically, the BTBR strain is also characterized by a complete absence of the corpus callosum. The goal of this study was to identify novel molecular and cellular changes in the BTBR mouse, focusing on neuronal, synaptic, glial and plasticity markers in the limbic system as a model for identifying putative molecular and cellular substrates associated with autistic behaviors.
Methods:
Forebrains of 8 to 10-week-old male BTBR and age-matched C57Bl/6J control mice were evaluated by immunohistochemistry using free-floating and paraffin embedded sections. Twenty antibodies directed against antigens specific to neurons, synapses and glia were used. Nissl, Timm and acetylcholinesterase (AchE) stains were performed to assess cytoarchitecture, mossy fibers and cholinergic fiber density, respectively. In the hippocampus, quantitative stereological estimates for the mitotic marker bromodeoxyuridine (BrdU) were performed to determine hippocampal progenitor proliferation, survival and differentiation, and brain-derived neurotrophic factor (BDNF) mRNA was quantified by in situ hybridization. Quantitative image analysis was performed for NG2, doublecortin (DCX), NeuroD, GAD67 and Poly-Sialic Acid Neural Cell Adhesion Molecule (PSA-NCAM).
Results:
In midline structures including the region of the absent corpus callosum of BTBR mice, the myelin markers 2&apos;,3&apos;-cyclic nucleotide 3&apos;-phosphodiesterase (CNPase) and myelin basic protein (MBP) were reduced, and the oligodendrocyte precursor NG2 was increased. MBP and CNPase were expressed in small ectopic white matter bundles within the cingulate cortex. Microglia and astrocytes showed no evidence of gliosis, yet orientations of glial fibers were altered in specific white-matter areas. In the hippocampus, evidence of reduced neurogenesis included significant reductions in the number of doublecortin, PSA-NCAM and NeuroD immunoreactive cells in the subgranular zone of the dentate gyrus, and a marked reduction in the number of 5-bromo-2&apos;-deoxyuridine (BrdU) positive progenitors. Furthermore, a significant and profound reduction in BDNF mRNA was seen in the BTBR dentate gyrus. No significant differences were seen in the expression of AchE, mossy fiber synapses or immunoreactivities of microtubule-associated protein MAP2, parvalbumin and glutamate decarboxylase GAD65 or GAD67 isoforms.
Conclusions:
We documented modest and selective alterations in glia, neurons and synapses in BTBR forebrain, along with reduced neurogenesis in the adult hippocampus. Of all markers examined, the most distinctive changes were seen in the neurodevelopmental proteins NG2, PSA-NCAM, NeuroD and DCX. Our results are consistent with aberrant development of the nervous system in BTBR mice, and may reveal novel substrates to link callosal abnormalities and autistic behaviors. The changes that we observed in the BTBR mice suggest potential novel therapeutic strategies for intervention in autism spectrum disorders.</description>
        <link>http://www.molecularautism.com/content/2/1/7</link>
                <dc:creator>Diane Stephenson</dc:creator>
                <dc:creator>Sharon O'Neill</dc:creator>
                <dc:creator>Sapna Narayan</dc:creator>
                <dc:creator>Aadhya Tiwari</dc:creator>
                <dc:creator>Elizabeth Arnold</dc:creator>
                <dc:creator>Harry Samaroo</dc:creator>
                <dc:creator>Fu Du</dc:creator>
                <dc:creator>Robert Ring</dc:creator>
                <dc:creator>Brian Campbell</dc:creator>
                <dc:creator>Mathew Pletcher</dc:creator>
                <dc:creator>Vidita Vaidya</dc:creator>
                <dc:creator>Daniel Morton</dc:creator>
                <dc:source>Molecular Autism 2011, null:7</dc:source>
        <dc:date>2011-05-16T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/2040-2392-2-7</dc:identifier>
                                <prism:require>/content/figures/2040-2392-2-7-toc.gif</prism:require>
                <prism:publicationName>Molecular Autism</prism:publicationName>
        <prism:issn>2040-2392</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>7</prism:startingPage>
        <prism:publicationDate>2011-05-16T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.molecularautism.com/content/2/1/18">
        <title>An X-chromosome-wide association study in autism families identifies TBL1X as a novel autism spectrum disorder candidate gene in males</title>
        <description>Background:
Autism spectrum disorder (ASD) is a complex neurodevelopmental disorder with a strong genetic component. The skewed prevalence toward males and evidence suggestive of linkage to the X chromosome in some studies suggest the presence of X-linked susceptibility genes in people with ASD.
Methods:
We analyzed genome-wide association study (GWAS) data on the X chromosome in three independent autism GWAS data sets: two family data sets and one case-control data set. We performed meta- and joint analyses on the combined family and case-control data sets. In addition to the meta- and joint analyses, we performed replication analysis by using the two family data sets as a discovery data set and the case-control data set as a validation data set.
Results:
One SNP, rs17321050, in the transducin &#946;-like 1X-linked (TBL1X) gene [OMIM:300196] showed chromosome-wide significance in the meta-analysis (P value = 4.86 &#215; 10-6) and joint analysis (P value = 4.53 &#215; 10-6) in males. The SNP was also close to the replication threshold of 0.0025 in the discovery data set (P = 5.89 &#215; 10-3) and passed the replication threshold in the validation data set (P = 2.56 &#215; 10-4). Two other SNPs in the same gene in linkage disequilibrium with rs17321050 also showed significance close to the chromosome-wide threshold in the meta-analysis.
Conclusions:
TBL1X is in the Wnt signaling pathway, which has previously been implicated as having a role in autism. Deletions in the Xp22.2 to Xp22.3 region containing TBL1X and surrounding genes are associated with several genetic syndromes that include intellectual disability and autistic features. Our results, based on meta-analysis, joint analysis and replication analysis, suggest that TBL1X may play a role in ASD risk.</description>
        <link>http://www.molecularautism.com/content/2/1/18</link>
                <dc:creator>Ren-Hua Chung</dc:creator>
                <dc:creator>Deqiong Ma</dc:creator>
                <dc:creator>Kai Wang</dc:creator>
                <dc:creator>Dale Hedges</dc:creator>
                <dc:creator>James Jaworski</dc:creator>
                <dc:creator>John Gilbert</dc:creator>
                <dc:creator>Michael Cuccaro</dc:creator>
                <dc:creator>Harry Wright</dc:creator>
                <dc:creator>Ruth Abramson</dc:creator>
                <dc:creator>Ioanna Konidari</dc:creator>
                <dc:creator>Patrice Whitehead</dc:creator>
                <dc:creator>Gerard Schellenberg</dc:creator>
                <dc:creator>Hakon Hakonarson</dc:creator>
                <dc:creator>Jonathan Haines</dc:creator>
                <dc:creator>Margaret Pericak-Vance</dc:creator>
                <dc:creator>Eden Martin</dc:creator>
                <dc:source>Molecular Autism 2011, null:18</dc:source>
        <dc:date>2011-11-04T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/2040-2392-2-18</dc:identifier>
                            <dc:title>Novel candidate gene for autism</dc:title>
                            <dc:description>TBL1X, which is part of the Wnt signaling pathway, is identified as a candidate gene for autism spectrum disorder (ASD), in the largest chromosome-wide study of the X chromosome in association with ASD.</dc:description>
                <prism:require>/content/figures/2040-2392-2-18-toc.gif</prism:require>
                <prism:publicationName>Molecular Autism</prism:publicationName>
        <prism:issn>2040-2392</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>18</prism:startingPage>
        <prism:publicationDate>2011-11-04T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.molecularautism.com/content/1/1/12">
        <title>Fragile X and autism: Intertwined at the molecular level leading to targeted treatments</title>
        <description>Fragile X syndrome (FXS) is caused by an expanded CGG repeat (&gt; 200 repeats) in the 5&apos; untranslated portion of the fragile mental retardation 1 gene (FMR1), leading to deficiency or absence of the FMR1 protein (FMRP). FMRP is an RNA carrier protein that controls the translation of several other genes that regulate synaptic development and plasticity. Autism occurs in approximately 30% of FXS cases, and pervasive developmental disorder, not otherwise specified (PDD-NOS) occurs in an additional 30% of cases. Premutation repeat expansions (55 to 200 CGG repeats) may also give rise to autism spectrum disorders (ASD), including both autism and PDD-NOS, through a different molecular mechanism that involves a direct toxic effect of the expanded CGG repeat FMR1 mRNA. RNA toxicity can also lead to aging effects including tremor, ataxia and cognitive decline, termed fragile X-associated tremor ataxia syndrome (FXTAS), in premutation carriers in late life. In studies of mice bearing premutation expansions, there is evidence of early postnatal neuronal cell toxicity, presenting as reduced cell longevity, decreased dendritic arborization and altered synaptic morphology. There is also evidence of mitochondrial dysfunction in premutation carriers. Many of the problems with cellular dysregulation in both premutation and full mutation neurons also parallel the cellular abnormalities that have been documented in autism without fragile X mutations. Research regarding dysregulation of neurotransmitter systems in FXS, including the metabotropic glutamate receptor (mGluR)1/5 pathway and &#947; aminobutyric acid (GABA)A pathways, have led to new targeted treatments for FXS. Preliminary evidence suggests that these new targeted treatments will also be beneficial in non-fragile X forms of autism.</description>
        <link>http://www.molecularautism.com/content/1/1/12</link>
                <dc:creator>Randi Hagerman</dc:creator>
                <dc:creator>Gry Hoem</dc:creator>
                <dc:creator>Paul Hagerman</dc:creator>
                <dc:source>Molecular Autism 2010, null:12</dc:source>
        <dc:date>2010-09-21T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/2040-2392-1-12</dc:identifier>
                                <prism:require>/content/figures/2040-2392-1-12-toc.gif</prism:require>
                <prism:publicationName>Molecular Autism</prism:publicationName>
        <prism:issn>2040-2392</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>12</prism:startingPage>
        <prism:publicationDate>2010-09-21T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.molecularautism.com/content/3/1/1">
        <title>Optimizing the phenotyping of rodent ASD models: Enrichment analysis of mouse and human neurobiological phenotypes associated with high-risk autism genes identifies morphological, electrophysiological, neurological, and behavioral features</title>
        <description>Background:
There is interest in defining mouse neurobiological phenotypes useful for studying autism spectrum disorders (ASD) in both forward and reverse genetic approaches. A recurrent focus has been on high-order behavioral analyses, including learning and memory paradigms and social paradigms. However, well-studied mouse models, including for example Fmr1 knockout mice, do not show dramatic deficits in such high-order phenotypes, raising a question as to what constitutes useful phenotypes in ASD models.
Methods:
To address this, we made use of a list of 112 disease genes etiologically involved in ASD to survey, on a large scale and with unbiased methods as well as expert review, phenotypes associated with a targeted disruption of these genes in mice, using the Mammalian Phenotype Ontology database. In addition, we compared the results with similar analyses for human phenotypes.FindingsWe observed four classes of neurobiological phenotypes associated with disruption of a large proportion of ASD genes, including: (1) Changes in brain and neuronal morphology; (2) electrophysiological changes; (3) neurological changes; and (4) higher-order behavioral changes. Alterations in brain and neuronal morphology represent quantitative measures that can be more widely adopted in models of ASD to understand cellular and network changes. Interestingly, the electrophysiological changes differed across different genes, indicating that excitation/inhibition imbalance hypotheses for ASD would either have to be so non-specific as to be not falsifiable, or, if specific, would not be supported by the data. Finally, it was significant that in analyses of both mouse and human databases, many of the behavioral alterations were neurological changes, encompassing sensory alterations, motor abnormalities, and seizures, as opposed to higher-order behavioral changes in learning and memory and social behavior paradigms.
Conclusions:
The results indicated that mutations in ASD genes result in defined groups of changes in mouse models and support a broad neurobiological approach to phenotyping rodent models for ASD, with a focus on biochemistry and molecular biology, brain and neuronal morphology, and electrophysiology, as well as both neurological and additional behavioral analyses. Analysis of human phenotypes associated with these genes reinforced these conclusions, supporting face validity for these approaches to phenotyping of ASD models. Such phenotyping is consistent with the successes in Fmr1 knockout mice, in which morphological changes recapitulated human findings and electrophysiological deficits resulted in molecular insights that have since led to clinical trials. We propose both broad domains and, based on expert review of more than 50 publications in each of the four neurobiological domains, specific tests to be applied to rodent models of ASD.</description>
        <link>http://www.molecularautism.com/content/3/1/1</link>
                <dc:creator>Joseph Buxbaum</dc:creator>
                <dc:creator>Catalina Betancur</dc:creator>
                <dc:creator>Ozlem Bozdagi</dc:creator>
                <dc:creator>Nate Dorr</dc:creator>
                <dc:creator>Gregory Elder</dc:creator>
                <dc:creator>Patrick Hof</dc:creator>
                <dc:source>Molecular Autism 2012, null:1</dc:source>
        <dc:date>2012-02-20T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/2040-2392-3-1</dc:identifier>
                                <prism:require>/content/figures/2040-2392-3-1-toc.gif</prism:require>
                <prism:publicationName>Molecular Autism</prism:publicationName>
        <prism:issn>2040-2392</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>1</prism:startingPage>
        <prism:publicationDate>2012-02-20T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.molecularautism.com/content/1/1/13">
        <title>Elevated cortisol during play is associated with age and social engagement in children with autism</title>
        <description>Background:
The hallmark characteristic of autism is impaired reciprocal social interaction. While children find social interaction stress-reducing, many children with autism may find social interaction stress-inducing. The current study was designed to examine stress responsivity as measured by cortisol by comparing children with autism to neurotypical peers during an ecologically valid 20-minute playground paradigm.
Methods:
The experiment involved sets of three children: a child with autism, a neurotypical child, and a confederate. Participants included 45 prepubescent males between 8 and 12 years of age (21 with autism and 24 neurotypical children).
Results:
Children with autism showed fewer initiations (&#967;&#178;(1) = 4.03, P = 0.044), rejected initiations from others more (&#967;&#178;(1) = 7.10, P = 0.008) and spent less time interacting during motor (F(1,43) = 16.7, P = 0.0002) and cooperative (F(1,43) = 14.78, P = 0.0004) play. Repeated measures analysis of the cortisol values revealed a significant model (&#967;&#178;(4) = 22.76, P &lt; 0.0005) that included time of measurement, diagnosis and age as main effects and an interaction between diagnosis and age. Thus, as age increased among children with autism, they experienced enhanced cortisol levels while age did not modify expected cortisol levels for typical children. Stress responsivity was associated with more peripheral equipment play for motor (&#967;&#178;(3) = 12.3, P = 0.006) and cooperative (&#967;&#178;(3) = 8.24, P = 0.04) play as well as reduced nonverbal social skills during motor (&#967;&#178;(1) = 5.52, P = 0.018) and cooperative play (&#967;&#178;(1) = 4.53, P = 0.033).
Conclusions:
Overall, children with autism engaged in fewer social overtures and spent less time interacting than typically developing peers during play. The peer interaction paradigm resulted in significantly higher levels of cortisol in many children with autism. Distinct patterns emerged within the autism group based on developmental (older), biological (cortisol responder) and behavioral patterns (peripheral group interaction). The enhanced cortisol response was observed in children who voluntarily engaged in interaction; thus, it does not support the notion of a response to social threat. Rather, it appears to reflect attendant metabolic preparedness and enhanced arousal from engaging socially. The data suggest that many children with autism activate hypothalamic-pituitary-adrenal responses in relatively benign social situations, which appears to be a function of age and level of social engagement. The findings support the need to teach coping strategies in addition to fundamental social skills to youth with autism.</description>
        <link>http://www.molecularautism.com/content/1/1/13</link>
                <dc:creator>Blythe Corbett</dc:creator>
                <dc:creator>Clayton Schupp</dc:creator>
                <dc:creator>David Simon</dc:creator>
                <dc:creator>Niles Ryan</dc:creator>
                <dc:creator>Sally Mendoza</dc:creator>
                <dc:source>Molecular Autism 2010, null:13</dc:source>
        <dc:date>2010-09-27T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/2040-2392-1-13</dc:identifier>
                                <prism:require>/content/figures/2040-2392-1-13-toc.gif</prism:require>
                <prism:publicationName>Molecular Autism</prism:publicationName>
        <prism:issn>2040-2392</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>13</prism:startingPage>
        <prism:publicationDate>2010-09-27T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.molecularautism.com/content/1/1/15">
        <title>Haploinsufficiency of the autism-associated Shank3 gene leads to deficits in synaptic function, social interaction, and social communication</title>
        <description>Background:
SHANK3 is a protein in the core of the postsynaptic density (PSD) and has a critical role in recruiting many key functional elements to the PSD and to the synapse, including components of &#945;-amino-3-hydroxyl-5-methyl-4-isoxazole-propionic acid (AMPA), metabotropic glutamate (mGlu) and N-methyl-D-aspartic acid (NMDA) glutamate receptors, as well as cytoskeletal elements. Loss of a functional copy of the SHANK3 gene leads to the neurobehavioral manifestations of 22q13 deletion syndrome and/or to autism spectrum disorders. The goal of this study was to examine the effects of haploinsufficiency of full-length Shank3 in mice, focusing on synaptic development, transmission and plasticity, as well as on social behaviors, as a model for understanding SHANK3 haploinsufficiency in humans.
Methods:
We used mice with a targeted disruption of Shank3 in which exons coding for the ankyrin repeat domain were deleted and expression of full-length Shank3 was disrupted. We studied synaptic transmission and plasticity by multiple methods, including patch-clamp whole cell recording, two-photon time-lapse imaging and extracellular recordings of field excitatory postsynaptic potentials. We also studied the density of GluR1-immunoreactive puncta in the CA1 stratum radiatum and carried out assessments of social behaviors.
Results:
In Shank3 heterozygous mice, there was reduced amplitude of miniature excitatory postsynaptic currents from hippocampal CA1 pyramidal neurons and the input-output (I/O) relationship at Schaffer collateral-CA1 synapses in acute hippocampal slices was significantly depressed; both of these findings indicate a reduction in basal neurotransmission. Studies with specific inhibitors demonstrated that the decrease in basal transmission reflected reduced AMPA receptor-mediated transmission. This was further supported by the observation of reduced numbers of GluR1-immunoreactive puncta in the stratum radiatum. Long-term potentiation (LTP), induced either with &#952;-burst pairing (TBP) or high-frequency stimulation, was impaired in Shank3 heterozygous mice, with no significant change in long-term depression (LTD). In concordance with the LTP results, persistent expansion of spines was observed in control mice after TBP-induced LTP; however, only transient spine expansion was observed in Shank3 heterozygous mice. Male Shank3 heterozygotes displayed less social sniffing and emitted fewer ultrasonic vocalizations during interactions with estrus female mice, as compared to wild-type littermate controls.
Conclusions:
We documented specific deficits in synaptic function and plasticity, along with reduced reciprocal social interactions in Shank3 heterozygous mice. Our results are consistent with altered synaptic development and function in Shank3 haploinsufficiency, highlighting the importance of Shank3 in synaptic function and supporting a link between deficits in synapse function and neurodevelopmental disorders. The reduced glutamatergic transmission that we observed in the Shank3 heterozygous mice represents an interesting therapeutic target in Shank3-haploinsufficiency syndromes.</description>
        <link>http://www.molecularautism.com/content/1/1/15</link>
                <dc:creator>Ozlem Bozdagi</dc:creator>
                <dc:creator>Takeshi Sakurai</dc:creator>
                <dc:creator>Danae Papapetrou</dc:creator>
                <dc:creator>Xiaobin Wang</dc:creator>
                <dc:creator>Dara Dickstein</dc:creator>
                <dc:creator>Nagahide Takahashi</dc:creator>
                <dc:creator>Yuji Kajiwara</dc:creator>
                <dc:creator>Mu Yang</dc:creator>
                <dc:creator>Adam Katz</dc:creator>
                <dc:creator>Maria Luisa Scattoni</dc:creator>
                <dc:creator>Mark Harris</dc:creator>
                <dc:creator>Roheeni Saxena</dc:creator>
                <dc:creator>Jill Silverman</dc:creator>
                <dc:creator>Jacqueline Crawley</dc:creator>
                <dc:creator>Qiang Zhou</dc:creator>
                <dc:creator>Patrick Hof</dc:creator>
                <dc:creator>Joseph Buxbaum</dc:creator>
                <dc:source>Molecular Autism 2010, null:15</dc:source>
        <dc:date>2010-12-17T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/2040-2392-1-15</dc:identifier>
                            <dc:title>How a genetic mutation may lead to autism</dc:title>
                            <dc:description>Recent discovery may explain how mutations affecting SHANK3 may lead to autism spectrum disorders</dc:description>
                <prism:require>/content/figures/2040-2392-1-15-toc.gif</prism:require>
                <prism:publicationName>Molecular Autism</prism:publicationName>
        <prism:issn>2040-2392</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>15</prism:startingPage>
        <prism:publicationDate>2010-12-17T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.molecularautism.com/content/2/1/4">
        <title>Review of neuroimaging in Autism Spectrum Disorders: what have we learned and where we go from here</title>
        <description>Autism spectrum disorder (ASD) refers to a syndrome of social communication deficits and repetitive behaviors or restrictive interests. It remains a behaviorally defined syndrome with no reliable biological markers. The goal of this review is to summarize the available neuroimaging data and examine their implication for our understanding of the neurobiology of ASD.Although there is variability in the literature on structural magnetic resonance literature (MRI), there is evidence of volume abnormalities in both grey and white matter, with a suggestion of some region-specific differences. Early brain overgrowth is probably the most replicated finding in a subgroup of people with ASD, and new techniques, such as cortical-thickness measurements and surface morphometry have begun to elucidate in more detail the patterns of abnormalities as they evolve with age, and are implicating specific neuroanatomical or neurodevelopmental processes. Functional MRI and diffusion tensor imaging techniques suggest that such volume abnormalities are associated with atypical functional and structural connectivity in the brain, and researchers have begun to use magnetic resonance spectroscopy (MRS) techniques to explore the neurochemical substrate of such abnormalities. The data from multiple imaging methods suggests that ASD is associated with an atypically connected brain. We now need to further clarify such atypicalities, and start interpreting them in the context of what we already know about typical neurodevelopmental processes including migration and organization of the cortex. Such an approach will allow us to relate imaging findings not only to behavior, but also to genes and their expression, which may be related to such processes, and to further our understanding of the nature of neurobiologic abnormalities in ASD.</description>
        <link>http://www.molecularautism.com/content/2/1/4</link>
                <dc:creator>Evdokia Anagnostou</dc:creator>
                <dc:creator>Margot Taylor</dc:creator>
                <dc:source>Molecular Autism 2011, null:4</dc:source>
        <dc:date>2011-04-18T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/2040-2392-2-4</dc:identifier>
                                <prism:require>/content/figures/2040-2392-2-4-toc.gif</prism:require>
                <prism:publicationName>Molecular Autism</prism:publicationName>
        <prism:issn>2040-2392</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>4</prism:startingPage>
        <prism:publicationDate>2011-04-18T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <cc:License rdf:about="http://creativecommons.org/licenses/by/2.0/">
        <cc:permits rdf:resource="http://creativecommons.org/ns#Reproduction" />
        <cc:permits rdf:resource="http://creativecommons.org/ns#Distribution" />
        <cc:permits rdf:resource="http://creativecommons.org/ns#DerivativeWorks" />
    </cc:License>
</rdf:RDF>

